1. Home
  2. NTR vs BIIB Comparison

NTR vs BIIB Comparison

Compare NTR & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nutrien Ltd.

NTR

Nutrien Ltd.

HOLD

Current Price

$59.28

Market Cap

26.6B

Sector

Industrials

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$180.05

Market Cap

24.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NTR
BIIB
Founded
2017
1978
Country
Canada
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
26.6B
24.2B
IPO Year
N/A
1991

Fundamental Metrics

Financial Performance
Metric
NTR
BIIB
Price
$59.28
$180.05
Analyst Decision
Hold
Buy
Analyst Count
17
23
Target Price
$63.76
$176.48
AVG Volume (30 Days)
2.5M
2.0M
Earning Date
11-05-2025
10-30-2025
Dividend Yield
3.68%
N/A
EPS Growth
150.34
N/A
EPS
3.70
10.97
Revenue
$25,671,000,000.00
$10,065,900,000.00
Revenue This Year
$6.21
$2.97
Revenue Next Year
$1.31
N/A
P/E Ratio
$16.02
$16.42
Revenue Growth
0.45
4.77
52 Week Low
$43.70
$110.04
52 Week High
$65.08
$185.17

Technical Indicators

Market Signals
Indicator
NTR
BIIB
Relative Strength Index (RSI) 57.34 72.54
Support Level $54.52 $165.75
Resistance Level $60.35 $183.93
Average True Range (ATR) 1.42 5.70
MACD 0.31 0.91
Stochastic Oscillator 75.48 81.64

Price Performance

Historical Comparison
NTR
BIIB

About NTR Nutrien Ltd.

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients—nitrogen, potash, and phosphate—although its main focus is potash, where it is the global leader in installed capacity with a roughly 20% market share. The company is also the largest agricultural retailer in North America and Australia, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: